Bladder Cancer Trial, Recruiting NCT05621837 Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT05621837
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with certain advanced or spreading cancers, confirmed by laboratory testing of tissue — these cancers include melanoma, breast cancer that no longer responds to hormone treatment, kidney cancer, bladder cancer, head and neck cancer, or non-small cell lung cancer (including some cases suitable for surgery)
  • People who are willing and able to follow the study requirements as set out in the protocol
  • People who have a stored tumour tissue sample (a type called FFPE) available for research testing
  • People aged between 18 and 90 years old at the time of joining
  • People whose general physical functioning falls within an acceptable range, as measured by a standard medical scale (ECOG score of 2 or below — confirm with trial site what this means for individual circumstances)
  • People who are able to understand and sign an informed consent form
  • People who agree to take part in a survey about social, economic, and psychological factors

Who may not be able to join:

  • People with a known history of HIV infection
  • People with serious neurological or psychiatric conditions
  • People who are pregnant or currently breastfeeding
  • People who are unable or unwilling to provide written informed consent
  • People who are unable or unwilling to attend regular follow-up appointments at the same trial centre

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori - Milan

Phone: +3902/23903245

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Registry
ClinicalTrials.gov
Start date
10 March 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Immunological endpoint; Immunological endpoint; Immunological endpoint; Immunological endpoint; Clinical endpoint_PFS; Clinical endpoint_OS; Clinical endpoint_ORR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov